SEC Form 4 · accession 0000905148-26-003548

Attovia Therapeutics, Inc. · ATTO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Aug 6, 2026

Accepted (ET)

Aug 10, 2026 · 4:12 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0002058707

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Aug 6, 2026	C	2,311,870	—	A	2,311,870	D
Common Stock^F1,F2	Aug 6, 2026	C	821,998	—	A	3,133,868	D
Common Stock^F1,F2	Aug 6, 2026	C	665,147	—	A	3,799,015	D
Common Stock^F2	Aug 6, 2026	P	382,352	$17.00	A	4,181,367	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F2,F1	—	Aug 6, 2026	C	21,477,273	D	—	—	Common Stock	2,311,870	D
Series B Preferred Stock^F2,F1	—	Aug 6, 2026	C	7,636,362	D	—	—	Common Stock	821,998	D
Series C Preferred Stock^F2,F1	—	Aug 6, 2026	C	6,179,219	D	—	—	Common Stock	665,147	D

F1In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.
F2These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.